Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib First-Line in EGFR-Mutated NSCLC
NCT01310036Phase 2Completed
- Sponsor
- Roche
- Start
- Apr 2011
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Apr 2011; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01310036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01310036.